shenzhen oncovent biomedical technology co., ltd established in july 2016 and located in the shenzhen qianhai development zone.
oncovent is leveraging its technology platform of monoclonal antibodies (mab) to develop clinical-stage therapeutic vaccines and immuno-oncology combination therapies.
at present, a number of the oncovent’s drug candidates are already in clinical development.
chief executive officer
over 20 years of experience in the formulation of clinical development and commercialization strategies.
while serving as vice president of corporate development at cstone pharmaceuticals, ms. han made significant contribution to the trial design of a lead asset for the treatment of first-line esophageal squamous cell carcinoma by building effective business insights capabilities for the company, shortening the asset’s journey-to-nda submission by seven quarters.
mechanism:a monoclonal antibody that activates ca123-specific t cell immune response.
designation:orphan drug designations by the u.s. fda and ema of the eu.
indication:first-line treatment for patients with advanced primary ovarian cancer. oregovomab is currently being evaluated in a global multicenter phase iii study (the flora-5 trial; nct04498117, 2020-002270-26). the study is designed to assess the potential clinical benefits of oregovomab in combination with standard chemotherapy regimen (carboplatin plus paclitaxel) in patients with advanced first-line epithelial ovarian cancer, fallopian tube carcinoma, or peritoneal carcinoma.
clinical progress: as of june 29, 2022, the study has enrolled over 330 patients from 130 centers in argentina, belgium, brazil, canada, chile, czech republic, hungary, italy, south korea, mexico, poland, spain, taiwan, and the united states.